title: [Cancer-associated gene abnormalities and chemosensitivity].
abstract: One of the most important clinical issues in cancer chemotherapy is the presence of intrinsic resistance or the appearance of acquired resistance against chemotherapy. As for intrinsic resistance, we had to perform direct chemo-sensitivity testing, or had to rely on the knowledge empirically acquired from randomized clinical trials. However, molecular or genetic markers associated with chemo-sensitivity have been reported recently. For example, inactivation of p53 or GML gene has been reported to be associated with chemo-resistance. Overexpression of topo-isomerase I has been reported to be associated with chemo-sensitivity to Topo I inhibitor. Overexpression of Thymidine Phosphorylase has been found to be associated with chemo-sensitivity to prodrug of 5-FU. By checking the status of such chemo-sensitivity markers prior to chemotherapy, it would be possible to predict the chemotherapeutic effect and even the necessity of the chemotherapy in the near future. In this article, we review the chemo-sensitivity markers reported so far, and methodology contributing to the discovery of new chemo-sensitivity markers. As a clinical study, 11 cases of ovarian cancer with high sensitivity to cisplatin-based chemotherapy and 29 cases of ovarian cancer with chemoresistance were analyzed by Comparative Genomic Hybridization (CGH). Copy number decrease in Xp, and copy number increase in 19q were observed in 13, 12 out of 29 resistant cases (45, 41%) and zero, 1 out of 11 sensitive cases (0, 9%), suggesting that -Xp and +19q were likely to be a genetic event associated with intrinsic drug-resistance (p = 0.006, 0.05, respectively). This effort should contribute to the discovery of new chemo-sensitivity and resistance markers.
authors.affiliation: Dept. of Gynecology, Sasaki Institute Kyoundo Hospital, Tokyo, Japan.
authors.forename: M
authors.initials: M
authors.lastname: Sakamoto
authors.forename: K
authors.initials: K
authors.lastname: Umayahara
authors.forename: H
authors.initials: H
authors.lastname: Sakamoto
authors.forename: K
authors.initials: K
authors.lastname: Kawasaki
authors.forename: Y
authors.initials: Y
authors.lastname: Suehiro
authors.forename: T
authors.initials: T
authors.lastname: Kunugi
authors.forename: T
authors.initials: T
authors.lastname: Akiya
authors.forename: H
authors.initials: H
authors.lastname: Iwabuchi
authors.forename: H
authors.initials: H
authors.lastname: Sakunaga
authors.forename: T
authors.initials: T
authors.lastname: Muroya
authors.forename: Y
authors.initials: Y
authors.lastname: Kikuchi
authors.forename: T
authors.initials: T
authors.lastname: Sugishita
authors.forename: Y
authors.initials: Y
authors.lastname: Tenjin
authors.forename: J W
authors.initials: JW
authors.lastname: Gray
authors.forename: T
authors.initials: T
authors.lastname: Tanaka
mesh_terms: D000970:Antineoplastic Agents / Q000494:pharmacology*; D002945:Cisplatin / Q000494:pharmacology; D004264:DNA Topoisomerases, Type I / Q000235:genetics; D004250:DNA Topoisomerases, Type II / Q000235:genetics; D004268:DNA-Binding Proteins; D019008:Drug Resistance, Neoplasm / Q000235:genetics*; D004354:Drug Screening Assays, Antitumor; D005260:Female; D019450:Genes, MDR; D016158:Genes, p53; D006801:Humans; D009369:Neoplasms / Q000235:genetics* / Q000473:pathology; D010051:Ovarian Neoplasms / Q000235:genetics / Q000473:pathology; D011506:Proteins / Q000235:genetics; D012313:RNA; D019098:Telomerase; D014407:Tumor Cells, Cultured; D016159:Tumor Suppressor Protein p53 / Q000235:genetics
chemical_list: D000970:Antineoplastic Agents; D004268:DNA-Binding Proteins; D011506:Proteins; D016159:Tumor Suppressor Protein p53; C422952:telomerase RNA; D012313:RNA; D019098:Telomerase; D004264:DNA Topoisomerases, Type I; D004250:DNA Topoisomerases, Type II; D002945:Cisplatin